Neopharmed Gentili acquires Lormetazepam product

/Neopharmed Gentili acquires Lormetazepam product

Neopharmed Gentili acquires Lormetazepam product portfolio to strengthen its neurology division


  • Neopharmed Gentili acquires rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan).
  • The transaction allows Neopharmed Gentili to strengthen its portfolio in the neuro-psychiatric area with high value-added drugs for the treatment of insomnia.

Milan, 1st March, 2022- Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Bayer for the acquisition of the rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia.

The agreement is the result of a close collaboration with Bayer, which will also ensure in both Countries a smooth transition of the assets without disruption in the market. Closing is subject to customary conditions.

The transaction confirms the company’s strong growth momentum thanks to its consolidated experience in M&A and licensing transactions, especially with multinational partners.

“This agreement confirms Neopharmed Gentili’s intention to continue its long-standing development path, which includes the expansion of its therapeutic offering with high value-added products in several areas, including the neuro-psychiatric area where we are already present with drugs of proven efficacy for the treatment of anxiety disorders and depression,” said Alessandro Del Bono, CEO of Neopharmed Gentili. – “This transaction also confirms the company’s ability to execute extraordinary financial transactions that allow Neopharmed to continue a stable and lasting growth.”


About Neopharmed Gentili

Neopharmed Gentili is a pharmaceutical company founded in Italy with historic roots in its territory, which is rapidly expanding beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility and care are the pillars that guide Neopharmed Gentili’s mission to improve the health and quality of life of patients, caregivers and healthcare personnel. Neopharmed Gentili’s ambition is to help people live long and healthy lives, acting with ethical value and scientific precision, and offering solutions with high therapeutic value.


For further information:

Neopharmed Gentili S.p.A.
Ottavia Landi
Director of External Relations and Institutional Affairs
Mob. 342.3409572 |

Neopharmed Gentili press office
Value Relations
Angela Del Giudice
Mob. 392.6858392 |

Image Building
Cristina Fossati, Luisella Murtas
Tel.:  02 89011300 |

Download the full press review
Archive of news and press releases